This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.2 / Special Copayment Reduction: V009 |
| B. Synonyms | Stable factor deficiency, FVII deficiency, Hypoproconvertinemia, Proconvertin deficiency |
| C. Adult onset | High — mild cases are often discovered during surgery or childbirth in adulthood; discovered incidentally on preoperative testing from isolated PT prolongation |
| 1. History | 2. Causes |
| 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms |
| 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment |
| 11. Prognosis | 12. Prevention |
| 13. References | |
Factor VII (FVII) originated in 1951 when Alexander and Goldstein discovered a new coagulation factor in a patient with a bleeding tendency and named it serum prothrombin conversion accelerator (SPCA). Around the same time, several researchers described it under names such as proconvertin and stable factor. The name 'Stable factor' derives from the property that FVII is stably preserved in serum and contributes to serum coagulant activity, in contrast to FV, the 'labile factor', which is unstable in serum and easily degraded. The contrast between these two factors was an important criterion for classifying factors in early coagulation research.
In the 1960s–70s, as it was revealed that FVII is activated through binding to tissue factor (TF), FVII became established as the initiating factor of the extrinsic coagulation pathway. In 1984, Broze and Majerus showed that the TF-FVIIa complex initiates the common coagulation pathway by directly activating FX. Later, in the cell-based model of coagulation, the TF-FVIIa complex was redefined as central to the initiation phase of the coagulation response.
In 1988, Hedner and Kisiel found that administering very high doses of FVIIa to hemophilia patients with inhibitors could induce hemostasis by bypassing FIX·FX. This led to the development of recombinant FVIIa (rFVIIa, NovoSeven), which received an indication for hemophilia patients with inhibitors in 1996. The indication for rFVIIa was later expanded to the treatment of congenital FVII deficiency, and it is used as the first recombinant therapy dedicated to FVII deficiency. The history of this drug's development is an important historical achievement where FVII research and innovation in hemophilia treatment meet.
Congenital FVII deficiency is caused by pathogenic variants in the F7 gene (chromosome 13q34). To date, about 200 different variants (missense, nonsense, frameshift, splicing variants, large deletions) have been reported. FVII deficiency is the most common disease among the rare coagulation factor deficiencies under code D68.2, with a worldwide prevalence of about 1 in 500,000 to 1 in 1 million. The frequency is relatively high in regions with high rates of consanguineous marriage, such as the Middle East, Iran and southern Italy.
Among the vitamin K-dependent coagulation factors, FVII has the shortest half-life (3–6 hours). Because of this property, FVII decreases first and fastest with vitamin K deficiency or warfarin administration. Thus, early in warfarin therapy, FVII alone decreases and PT (INR) is prolonged, but FII, which is most important for the antithrombotic effect, is still sufficiently maintained, so the thrombotic risk early in therapy is actually higher (the so-called early warfarin thrombotic paradox). FVII also characteristically decreases early in liver failure and DIC, and rarely autoantibodies against FVII form, causing acquired deficiency.
Among the vitamin K-dependent coagulation factors, the half-life of FVII (3–6 hours) is overwhelmingly shorter than those of FX (40–45 hours), FIX (18–24 hours) and FII (60–72 hours). When warfarin is started, synthesis of new vitamin K-dependent coagulation factors is inhibited, so FVII, with the shortest half-life, is depleted from the blood first. This is why PT (INR) is prolonged by the isolated decrease in FVII within the first 24–48 hours of warfarin therapy. Paradoxically, during this period prothrombin (FII) levels are maintained rather than an antithrombotic effect being achieved, so the thrombotic risk may be high, which is the basis for recommending concurrent heparin administration early in warfarin therapy.
The F7 gene is located on chromosome 13q34 and consists of 9 exons. Interestingly, the F10 (factor X) gene is located immediately adjacent at the same chromosome 13q34 position, and the two genes are presumed to have diverged evolutionarily from a common ancestral gene. The FVII protein is a single-chain glycoprotein of about 50 kDa composed of a Gla domain (site of vitamin K-dependent γ-carboxylation), two EGF-like domains and a serine protease domain. The main site of protein expression is hepatocytes, with small amounts also expressed in monocytes and macrophages.
Congenital FVII deficiency follows an autosomal recessive inheritance pattern. Heterozygous carriers have FVII activity reduced to about 50% but are mostly asymptomatic. Clinical deficiency is expressed in homozygotes or compound heterozygotes, and severe bleeding occurs at FVII activity below 1%. Representative FVII variants include p.Arg304Gln (Arg353Gln) and p.Ala244Val, and in populations of Italian descent the heterozygote frequency of the p.Arg304Gln variant is relatively high at about 1–2%. When heterozygous carriers take warfarin, the FVII decrease may be greater, increasing the bleeding risk.
In FVII deficiency, the correlation between genotype and clinical phenotype is not simple. Even among patients with the same variant, the degree of clinical bleeding sometimes differs greatly, because complex factors such as platelet function, levels of other coagulation factors, vascular endothelial function and living environment affect the bleeding phenotype. In particular, the fact that the correlation between FVII activity and bleeding severity is less clear than in FVIII and FIX deficiency (hemophilia A, B) is a factor that makes treatment decisions difficult for patients with FVII deficiency.
Congenital FVII deficiency is the most common disease among the rare coagulation factor deficiencies sharing code D68.2. The worldwide prevalence is estimated at about 1 in 500,000 for symptomatic severe deficiency, and about 1 in 500 to 1 in 1,000 including heterozygous carriers. In the 2012 EN-RBD registry data, FVII deficiency accounted for the largest share, about 30%, of patients with rare coagulation factor deficiencies. The frequency is higher in the Mediterranean region, Iran and the Indian subcontinent, which is associated with the practice of consanguineous marriage.
Because it is autosomal recessive, males and females are affected equally. Severe deficiency (FVII <1%) presents in the neonatal period or infancy, but moderate (1–10%) and mild (10–50%) deficiencies are not uncommonly first diagnosed in adulthood. In particular, cases in which FVII deficiency is first identified when isolated PT (INR) prolongation is found incidentally on routine preoperative testing are much more common than for the other factor deficiencies under code D68.2. In female patients, heavy menstrual bleeding or excessive postpartum bleeding sometimes prompts the diagnosis.
FVII deficiency is discovered incidentally on preoperative testing relatively more often than other rare coagulation factor deficiencies. This is because FVII deficiency shows the characteristic finding of isolated PT prolongation, and PT (or INR) is included among the standard preoperative tests. When a previously asymptomatic patient has a PT INR prolonged to 1.5 or higher with a normal aPTT, FVII deficiency should be suspected first. In these cases, many patients have mild deficiency (FVII 10–50%) and go for decades without everyday bleeding before receiving their first diagnosis.
FVII alone has very low coagulant activity, but it is rapidly activated when it binds tissue factor (TF) exposed after vascular injury. The TF-FVIIa complex directly activates FX to FXa and FIX to FIXa, initiating the coagulation pathway. Among the activation pathways of FX, the extrinsic pathway via TF-FVIIa is the starting point of the initial thrombin burst. In the cell-based model of coagulation, TF-expressing cells (fibroblasts and monocytes at the site of injury) provide the stage for this initiation process.
Among the vitamin K-dependent coagulation factors, FVII has the shortest plasma half-life (3–6 hours). This short half-life has several important clinical implications. First, when liver function deteriorates abruptly, FVII decreases first and PT responds sensitively, so FVII levels or PT are early sensitive indicators of acute liver failure. Second, in patients with FVII deficiency, recombinant FVIIa has a short duration of action, so frequent dosing is needed. Third, when warfarin is stopped, FVII recovers fastest and contributes most to normalization of the PT.
When FVII is deficient, initiation of the extrinsic coagulation pathway is blocked and initial thrombin generation is severely reduced. At FVII activity below 1%, serious spontaneous bleeding occurs, and at 1–10%, excessive bleeding mainly after surgery, trauma or childbirth appears. Interestingly, in FVII deficiency the intrinsic pathway (FIX-FVIII dependent) is maintained, so the aPTT is normal and only the PT, which reflects the impaired extrinsic pathway, is prolonged. This is the most characteristic laboratory finding of FVII deficiency, and isolated PT prolongation suggests FVII deficiency (or, rarely, severe isolated abnormalities of FII, FV or FX).
In severe deficiency with FVII activity below 1%, serious bleeding symptoms appear from the neonatal period or infancy. Intracranial hemorrhage (ICH) is the most lethal complication of FVII deficiency and is reported to occur in about 16% of all patients with FVII deficiency. Umbilical cord bleeding in the neonatal period, recurrent hemarthrosis, intramuscular hematomas and gastrointestinal bleeding occur. Hemarthrosis in FVII deficiency is less frequent than in hemophilia A·B but can occur in severe deficiency.
In moderate deficiency with FVII activity of 1–10%, the main symptom is excessive bleeding after surgery, trauma, dental procedures or childbirth. Nosebleeds, gum bleeding and subcutaneous hematomas may recur. In female patients, heavy menstrual bleeding is a common initial symptom. In mild deficiency with FVII activity of 10–50%, most patients live without everyday bleeding symptoms and are discovered incidentally by PT prolongation before surgery. Importantly, in FVII deficiency, compared with FV deficiency, the bleeding phenotype is not necessarily proportional to activity at the genetic level.
During early warfarin administration (before the target INR is reached), the isolated decrease in FVII prolongs the PT so the INR appears high, but the actual antithrombotic effect (decrease of FII, FX, FIX) is insufficient. In this so-called 'warfarin paradox' situation, the thrombotic risk may instead increase due to the earlier decrease in protein C. In acquired FVII reduction due to liver failure, symptoms of reduced liver function such as jaundice and ascites accompany the bleeding symptoms.
Physical examination findings in patients with FVII deficiency vary with severity. In severe deficiency, extensive ecchymoses, joint swelling and deformity, and neurological sequelae after intracranial hemorrhage may appear. Physical examination of patients with mild to moderate deficiency is generally normal, or petechiae, hypertrophic gum bleeding and oral mucosal hematomas are found only on careful inspection. FVII is a vitamin K-dependent factor, but in congenital cases of isolated deficiency the other vitamin K-dependent factors are normal, so the absence of jaundice or signs of liver failure is an important negative sign.
The most characteristic laboratory finding of FVII deficiency is isolated PT (INR) prolongation. The aPTT is normal because it reflects the intrinsic pathway, which does not depend on FVII. When isolated PT prolongation is confirmed, the differential diagnosis is ① congenital FVII deficiency, ② warfarin or vitamin K antagonist use (FVII decreases first; aPTT may also be mildly prolonged), ③ early liver failure (isolated decrease in FVII), and ④ autoantibodies against FVII (very rare). In congenital FVII deficiency, confirming that only FVII activity is reduced and the other vitamin K-dependent factors (FII, FIX, FX) are normal brings one close to a definitive diagnosis.
In severe FVII deficiency, recurrent hemarthrosis can lead to joint X-ray findings similar to hemophilic arthropathy (joint space narrowing, subchondral cysts), but in FVII deficiency it is relatively rare for arthropathy to progress as severely as in hemophilia A. When intracranial hemorrhage occurs, a hematoma is identified on brain CT or MRI. Visceral bleeding and peritoneal hematomas can be identified on abdominal CT.
Screening for FVII deficiency starts from the finding of isolated PT prolongation (normal aPTT) measured preoperatively or during bleeding evaluation. When the PT INR exceeds 1.5 with an aPTT in the normal range, FVII deficiency is the first suspicion. If TT and fibrinogen are normal, fibrinogen abnormalities are excluded. Warfarin use, vitamin K deficiency and liver function abnormalities are excluded first, and congenital FVII deficiency is considered among the rest.
If the PT corrects in the mixing test, a deficiency including FVII is likely. FVII-specific factor activity is then measured. FVII activity is measured by a PT-based clotting assay using FVII-deficient substrate plasma and brain thromboplastin. Comparing FVII antigen levels with activity can determine whether there is dysfunctional FVII (normal antigen, reduced activity). Checking vitamin K status (blood vitamin K concentration or remeasurement of PT 4–6 hours after vitamin K administration) helps distinguish congenital from acquired deficiency.
The evaluation flow for patients in whom isolated PT prolongation is found incidentally on preoperative testing is as follows: ① check history of warfarin or vitamin K antagonist use, ② liver function tests (ALT, AST, albumin, bilirubin), ③ mixing test (check whether PT corrects), ④ FVII-specific factor measurement, ⑤ if FVII deficiency is confirmed, take bleeding and family history, and ⑥ establish a treatment plan according to surgical risk and FVII level. When FVII activity is 10% or higher, rFVIIa pretreatment may not necessarily be needed for minor surgery, but individualized judgment is required.
Congenital FVII deficiency is confirmed in the following order: ① isolated PT (INR) prolongation (normal aPTT), ② reduced FVII activity on FVII-specific factor assay (below 50% of normal), ③ normal vitamin K status (no PT correction after vitamin K administration), ④ normal other vitamin K-dependent factors (FII, FIX, FX), and ⑤ identification of a pathogenic variant in the F7 gene. Severity classification: <1% severe, 1–10% moderate, 10–50% mild, >50% borderline or heterozygous carrier range.
Main differential diagnoses of isolated PT prolongation: ① warfarin or vitamin K deficiency (FII, FIX and FX also expected to be reduced; rapid correction after vitamin K administration), ② congenital FVII deficiency (only FVII reduced, other factors normal), ③ early liver failure (FVII sensitive, but accompanied by albumin and bilirubin abnormalities), ④ acquired FVII inhibitor (very rare; PT does not correct in the mixing test), ⑤ overexpression of the FVII-TF pathway inhibitor (TFPI) (theoretical; rare in actual clinical practice). Warfarin use is the acquired cause that must be excluded first.
The parents of confirmed patients, as heterozygous carriers, should undergo FVII activity testing. Screening of siblings is recommended. In patients of Italian, Iranian and Middle Eastern descent, testing for specific common variants (such as p.Arg304Gln) helps with faster diagnosis. For patients planning pregnancy, the possibility of preimplantation genetic diagnosis (PGT) or prenatal genetic diagnosis is discussed. Particular caution is needed because the FVII decrease is greater than predicted when heterozygous carriers take warfarin.
Currently the most preferred treatment for congenital FVII deficiency is intravenous administration of recombinant FVIIa (rFVIIa, NovoSeven). rFVIIa binds TF on the surface of TF-expressing cells to initiate a strong local coagulation response and also has a TF-independent mechanism that generates FXa directly on the surface of activated platelets. The dose is usually 15–30 mcg/kg injected intravenously every 2–3 hours, and frequent dosing is needed because of the short half-life of FVII. A plan for preoperative prophylactic dosing and postoperative additional dosing must be established.
Plasma-derived FVII concentrate is available in some European countries. Unlike rFVIIa, it mainly contains inactive FVII (zymogen) and acts by being activated in the body after binding to TF. In some countries, plasma-derived products have been reported to have a slightly longer half-life than rFVIIa, which may allow longer dosing intervals, but they are not used as widely as rFVIIa.
When rFVIIa or plasma-derived FVII concentrate is unavailable, fresh frozen plasma (FFP) is an alternative. FFP contains all coagulation factors and can be used to supply FVII, but large volumes are needed. Four-factor prothrombin complex concentrate (PCC) also contains FVII and can be used, but the risk of thrombotic complications must be taken into account. For prophylactic treatment, protocols using rFVIIa as routine prophylactic injections are applied in some patients with severe deficiency.
In severe FVII deficiency, when intracranial hemorrhage (ICH) occurs untreated, the risk of death or serious neurological sequelae is high. When prophylactic administration with rFVIIa is carried out, the frequency of ICH can be greatly reduced. Arthropathy is not as severe as in hemophilia A but can progress in severe deficiency. Because of the very short half-life of rFVIIa, adjusting the prophylactic dosing interval is a key challenge in treatment management.
Patients with FVII activity of 1–50% mostly have a good long-term prognosis with only appropriate management of hemostatic stress situations. In particular, in patients with mild FVII deficiency discovered incidentally before surgery (FVII 10–50%), rFVIIa may not be necessary for every surgery, and individualized management is provided according to the scale of surgery and FVII level. Because the correlation between bleeding phenotype and genotype values is less clear than in other factor deficiencies, the clinical bleeding history plays an important role in decisions on prophylactic treatment.
Because the half-life of rFVIIa (about 2–3 hours) is very short, patients with severe deficiency receiving prophylactic treatment require frequent routine injections, which affects quality of life. Clinical development of half-life-extended rFVIIa variants (FVIIa-albumin fusion protein, PEG-rFVIIa, etc.) is under way, which is expected to help improve patients' treatment convenience by reducing the number of doses.
In severe FVII deficiency (FVII <1%), regular prophylactic rFVIIa administration is recommended to prevent spontaneous bleeding, especially intracranial hemorrhage. Because of the very short half-life of rFVIIa (2–3 hours), optimizing the prophylactic dosing interval and dose is key. Clinically, dosing 1–3 times a week has been tried, and some institutions also use daily dosing protocols to prevent recurrent ICH. Candidates for prophylactic treatment are selected considering the economic burden and treatment convenience.
Before surgery, FVII activity is measured, a target level is set according to surgical risk, and an rFVIIa dosing plan is established. For major surgery, rFVIIa is given immediately before surgery with a target FVII activity of 15–25% or higher and is given repeatedly during surgery and for several days after surgery. For minor procedures (tooth extraction, small incisions), if the FVII level is 10–15% or higher, management with local hemostatic agents alone (fibrin glue, tranexamic acid mouth rinse) may be possible. Real-time monitoring with viscoelastic coagulation tests during surgery is recommended.
Through genetic counseling of families and identification of heterozygous carriers, newborns with FVII deficiency can be identified early and preventive measures can be taken before umbilical cord bleeding or intracranial hemorrhage occurs. Monitoring of FVII levels during pregnancy and delivery is recommended in heterozygous carrier women (FVII tends to increase slightly physiologically during pregnancy, which may make symptoms milder, but preparation is made for the risk of postpartum bleeding). Patients are educated about caution with activities that carry a bleeding risk, avoiding nonprescription NSAIDs and aspirin, and the importance of disclosing their history of FVII deficiency when receiving medical procedures.